Interv Akut Kardiol. 2017;16(3):103-105 | DOI: 10.36290/kar.2017.018

Antiplatelet therapy after BVS implantation

Martin Malý
Interní klinika 1. LF UK a Ústřední vojenské nemocnice – Vojenské fakultní nemocnice, Praha

It is not possible to simply adopt the guidelines’ for the length of dual antiplatelet therapy after metal stent implantation andapply them for the bioresorbable scaffold implantation. It is due to the differences in the technology and also the mechanicalproperties of scaffolds are changing during the process of resorption. In this report we focus on the interpretation of the limiteddata from the trials and we will try to formulate the recommendation for the antiplatelet treatment after the scaffold implantation.

Keywords: bioresorbable scaffolds, dual antiplatelet therapy, aspirin, ticagrelor, prasugrel

Received: September 5, 2017; Accepted: October 16, 2017; Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malý M. Antiplatelet therapy after BVS implantation. Interv Akut Kardiol. 2017;16(3):103-105. doi: 10.36290/kar.2017.018.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EATS Guidelines on Myocardial Revascularization. Eur Heart J 2014; 35: 2541-2619. Go to original source...
    2. Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focus Update on Duration of Dual Antiplatelet Therapy in Patinets With Coronary Artery Disease. J Am Coll Cardiol 2016; 68: 1082-1115. Go to original source... Go to PubMed...
    3. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol 2014; 64: e319-228.
    4. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the managememnt of acute coronary sydromes in patients presenting without persistent ST-segment Elevation of the European Society of Cardiology. Eur Heart J 2016; 37: 267-315. Go to original source... Go to PubMed...
    5. Lipinski MJ, Ecsarcega RD, Baxer NC, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable Vascular scaffold: a systematic review and meta-analysis. J Am Coll Cariol Intv 2016; 9: 12-14. Go to original source... Go to PubMed...
    6. Stone GW, Gao R, Kinura T, et al. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease; a patient-level. Pooled meta-analysis. Lancet 2016; 387: 1277-1289. Go to original source... Go to PubMed...
    7. Collet C, Asano T, Sotomi Y, et al. Early, late and very late incidence of bioresorbable scaffold thrombosis; a systematic review and meta-analysis of randomized clinical trials and observational studies. Minerva Cardioangiol 2016; 65: 32-51. Go to original source... Go to PubMed...
    8. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting metalic stent for the treatment of coronary artery stenoses (ABSORB II); a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet 2016; 387: 537-544. Go to original source...
    9. Tamburino C, Latib A, vanGeuns RJ, et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. Eurointervention 2015; 11: 45-52. Go to original source... Go to PubMed...
    10. Cortese B, Buccheri D, Stefanini GG, Mehran R. The contemporary pulse of bioresorbable-scaffold thrombosis among expert operators. J Am Coll Cardiol 2016; 67: 2905-2906. Go to original source... Go to PubMed...
    11. Onuma Y, Sotomi Y, Shiomi H, et al. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. Euro-Intervention 2016; 12: 1090-101. Go to original source... Go to PubMed...
    12. Chevalier B, Onuma Y, van Boven AJ, et al. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial. EuroIntervention 2016; 12: 1102-1107. Go to original source... Go to PubMed...
    13. Capodanno D, Angiolilo DJ. Antiplatelet therapy after implantation of bioresorbable Vascular scaffolds. J Am Coll Cardiol Intv 2017; 5: 425-437. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.